Abstract
The effective treatment of herpes simplex virus (HSV) infections generally involves the use of antiviral nucleoside drugs, but with increasing reports of antiviral resistance, the use of these drugs is challenged. Hence, a need arises to explore alternate treatment options. In this review we have discussed various targets that have been explored to control the HSV replication using siRNA therapeutics. We have also discussed the advantages of targeting a less explored UL10 gene to develop an alternate therapeutic intervention. Gene silencing can induce an inhibitory activity to virus spread and infection. The capacity and suitability of UL10 gene as siRNA induced silencing target in eliciting the desired antiviral effect in patients is identified and particularly discussed. The major challenge associated with the siRNA therapeutics is their delivery. The various viable delivery options, that are being explored in the recent times is summarized and different delivery pathways and strategies are reviewed as a part of the study.
Similar content being viewed by others
References
Blondeau C, Pelchen-Matthews A, Mlcochova P, Marsh M, Milne R, Towers G. Tetherin restricts herpes simplex virus 1 and Is antagonized by glycoprotein M. J Virol. 2013;87(24):13124–33.
Chouljenko D, Kim I, Chouljenko V, Subramanian R, Walker J, Kousoulas K. Functional hierarchy of herpes simplex virus 1 viral glycoproteins in cytoplasmic virion envelopment and egress. J Virol. 2012;86(8):4262–70.
Crump CM, Bruun B, Bell S, Pomeranz LE, Minson T, Browne HM. Alpha herpesvirus glycoprotein M causes the relocalization of plasma membrane proteins. J Gen Virol. 2004;85:3517–27.
da Silva A, Lopes JF, Paula VS. RNA interference inhibits herpes simplex virus type 1 isolated from saliva samples and mucocutaneous lesions. Braz J Infect Dis. 2014;18(4):441–4.
da Silva A, Raposo JV, Pereira TC, Pinto MA, de Paula VS. Effects of RNA interference therapy against herpes simplex virus type 1 encephalitis. Antivir Ther. 2016;20(3):225–35.
Duan F, Ni S, Nie Y, Huang Q, Wu K. Small interfering RNA targeting for infected-cell polypeptide 4 inhibits herpes simplex virus type 1 replication in retinal pigment epithelial cells. Clin Exp Ophthalmol. 2012;40(2):195–204.
El Kasmi I, Lippé R. Herpes simplex virus 1 gN partners with gM To modulate the viral fusion machinery. J Virol. 2015;89(4):2313–23.
Gavrilov K, Saltzman W. Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med. 2012;85:187–200.
Gilleron J, Paramasivam P, Zeigerer A, Querbes W, Marsico G, Andree C, Seifert S, Amaya P, Stöter M, Koteliansky V, Waldmann H, Fitzgerald K, Kalaidzidis Y, Akinc A, Maier M, Manoharan M, Bickle M, Zerial M. Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Res. 2015;43(16):7984–8001.
Hochberg CH, Schneider JA, Dandona R, Lakshmi V, Kumar GA, Sudha T, Akbar M, Ahmed GMM, Ramgopal SP, Armbruster B, Alary M, Dandona L. Population and dyadic-based seroincidence of herpes simplex virus-2 and syphilis in southern India. Sex Transm Infect. 2015;91(5):375–82.
Jiang Y, Huo S, Hardie J, Liang X, Rotello V. Progress and perspective of inorganic nanoparticle-based siRNA delivery systems. Expert Opin Drug Deliv. 2016;13(4):547–59.
Jin F, Li S, Zheng K, Zhuo C, Ma K, Chen M, Wang Q, Zhang P, Fan J, Ren Z, Wang Y. Silencing herpes simplex virus type 1 capsid protein encoding genes by siRNA: a promising antiviral therapeutic approach. PLOS ONE. 2014;9(5):96623.
Kim I, Chouljenko V, Walker J, Kousoulas K. Herpes simplex virus 1 glycoprotein M and the membrane-associated protein UL11 are required for virus-induced cell fusion and efficient virus entry. J Virol. 2013;87(14):8029–37.
Kodama Y, Shiokawa Y, Nakamura T, Kurosaki T, Aki K, Nakagawa H, Muro T, Kitahara T, Higuchi N, Sasaki H. Novel siRNA delivery system using a ternary polymer complex with strong silencing effect and no cytotoxicity. Biol Pharm Bull. 2014;37(8):1274–81.
Kozielski K, Tzeng S, Green J. Bioengineered nanoparticles for siRNA delivery. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnol. 2013;5(5):449–68.
Lau S, Crump C. HSV-1 gM and the gK/pUL20 complex are important for the localization of gD and gH/L to viral assembly sites. Viruses. 2015;7(3):915–38.
Leege T, Fuchs W, Granzow H, Kopp M, Klupp B, Mettenleiter T. Effects of simultaneous deletion of pUL11 and glycoprotein M on virion maturation of herpes simplex virus type 1. J Virol. 2008;83(2):896–907.
MacLean C, Robertson L, Jamieson F. Characterization of the UL10 gene product of herpes simplex virus type 1 and investigation of its role in vivo. J Gen Virol. 1993;74(6):975–83.
Paavilainen H, Lehtinen J, Romanovskaya A, Nygårdas M, Bamford DH, Poranen MM, Hukkanen V. Inhibition of clinical pathogenic herpes simplex virus 1 strains with enzymatically created siRNA pools. J Med Virol. 2016;88(12):2196–205.
Paavilainen H, Lehtinen J, Romanovskaya A, Nygårdas M, Bamford DH, Poranen MM, Hukkanen V. Topical treatment of herpes simplex virus infection with enzymatically created siRNA swarm. Antivir Ther. 2017;22(7):631–7.
Patwardhan V, Bhalla P. Role of type-specific herpes simplex virus-1 and 2 serology as a diagnostic modality in patients with clinically suspected genital herpes: a comparative study in Indian population from a tertiary care hospital. Indian J Pathol Microbiol. 2016;59(3):318–21.
Ren Y, Bell S, Zenner H, Lau S, Crump C. Glycoprotein M is important for the efficient incorporation of glycoprotein H–L into herpes simplex virus type 1 particles. J Gen Virol. 2011;93(2):319–29.
Salzano G, Costa D, Torchilin V. siRNA delivery by stimuli-sensitive nanocarriers. Curr Pharm Des. 2015;21(31):4566–73.
Saran N, Bupesh G, Magesh S, Vennila S, Anandharaj B, Anupama CP, Kaveri K, Gunasekaran P. Epidemiological studies and molecular characterization of herpes simplex virus among Urban population in Chennai, Tamilnadu. Epidemiol: Open Access. 2015;5(02):187.
Sarett S, Nelson C, Duvall C. Technologies for controlled, local delivery of siRNA. J Control Release. 2015;218:94–113.
Shim M, Kwon Y. Efficient and targeted delivery of siRNA in vivo. FEBS J. 2010;277(23):4814–27.
Song B, Liu X, Wang Q, Zhang R, Yang T, Han Z, Xu Y. Adenovirus-mediated shRNA interference against HSV-1 replication in vitro. J Neurovirol. 2016;22(6):799–807.
Striebinger H, Funk C, Raschbichler V, Bailer S. Subcellular trafficking and functional relationship of the HSV-1 glycoproteins N and M. Viruses. 2016;8(3):83.
Tatiparti K, Sau S, Kashaw S, Iyer A. siRNA delivery strategies: a comprehensive review of recent developments. Nanomaterials. 2017;7(4):77.
Wang J, Lu Z, Wientjes M, Au J. Delivery of siRNA therapeutics: barriers and carriers. AAPS J. 2010;12(4):492–503.
Wang Z, Fan P, Zhao Y, Zhang S, Lu J, Xie W, Jiang Y, Lei F, Xu N. NEAT1 modulates herpes simplex virus-1 replication by regulating viral gene transcription. Cell Mol Life Sci. 2017;74(6):1117–31.
Whitley R, Kimberlin D, Roizman B. Herpes simplex viruses. Clin Infect Dis. 1998;26(3):541–53.
Wu Y, Navarro F, Lal A, Basar E, Pandey RK, Manoharan M, Feng Y, Lee SJ, Lieberman J, Palliser D. Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe. 2009;5:84–94.
Xu C, Wang J. Delivery systems for siRNA drug development in cancer therapy. Asian J Pharm Sci. 2015;10(1):1–12.
Zhang Y, Lai W, Li H, Li G. Inhibition of herpes simplex virus type 1 by small interfering RNA. Clin Exp Dermatol. 2008;33(1):56–61.
Zhang J, Nagel C, Sodeik B, Lippe R. Early, active, and specific localization of herpes simplex virus type 1 gM to nuclear membranes. J Virol. 2009;83(24):12984–97.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Manda, V., Josyula, V. & Hariharapura, R. siRNA intervention inhibiting viral replication and delivery strategies for treating herpes simplex viral infection. VirusDis. 30, 180–185 (2019). https://doi.org/10.1007/s13337-018-00508-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13337-018-00508-z